当前位置: 首页 >> 检索结果
3101. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
作者: Mehreen S Datoo.;Alassane Dicko.;Halidou Tinto.;Jean-Bosco Ouédraogo.;Mainga Hamaluba.;Ally Olotu.;Emma Beaumont.;Fernando Ramos Lopez.;Hamtandi Magloire Natama.;Sophie Weston.;Mwajuma Chemba.;Yves Daniel Compaore.;Djibrilla Issiaka.;Diallo Salou.;Athanase M Some.;Sharon Omenda.;Alison Lawrie.;Philip Bejon.;Harish Rao.;Daniel Chandramohan.;Rachel Roberts.;Sandesh Bharati.;Lisa Stockdale.;Sunil Gairola.;Brian M Greenwood.;Katie J Ewer.;John Bradley.;Prasad S Kulkarni.;Umesh Shaligram.;Adrian V S Hill.; .
来源: Lancet. 2024年403卷10426期533-544页
Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enrolling over 4800 children across four countries followed for up to 18 months at seasonal sites and 12 months at standard sites.
3107. Anti-GABAA receptor encephalitis 14 months after allogeneic haematopoietic stem-cell transplant for acute myeloid leukaemia.
作者: Thilo Rusche.;Özgür Yaldizli.;Riccardo Galbusera.;Matthias Mutke.;Jörg P Halter.;Johanna Lieb.;Francesca Matteazzi.;Anne Stelmes.;Jan Bittner.;Pascale Grzonka.;Nicole Frank.;Dominik Cordier.;Jürgen Hench.;Stephan Frank.;Hans H Hirsch.;Urs Fischer.;Jens Kuhle.;Raoul Sutter.;Stephan Rüegg.;Urs Fisch.
来源: Lancet. 2024年403卷10425期469-470页 3120. Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial.
作者: Xiaolin Wei.;Joseph Paul Hicks.;Zhitong Zhang.;Victoria Haldane.;Pande Pasang.;Linhua Li.;Tingting Yin.;Bei Zhang.;Yinlong Li.;Qiuyu Pan.;Xiaoqiu Liu.;John Walley.;Jun Hu.
来源: Lancet. 2024年403卷10430期913-923页
WHO recommends that electronic medication monitors, a form of digital adherence technology, be used as a complement to directly observed treatment (DOT) for tuberculosis, as DOT is inconvenient and costly. However, existing evidence about the effectiveness of these monitors is inconclusive. Therefore, we evaluated the effectiveness of a comprehensive package based on electronic medication monitors among patients with tuberculosis in Tibet Autonomous Region (hereafter Tibet), China.
|